Bayer reported +2% (organic: +4%) higher sales at €46,769m and the gross profit margin improved from 54.4% to 56.6% in 2016. EBITDA rose +13% to €10,785m and net profit attributable to shareholders came in at €4,531m, up by +10%. Operating CF (+32% to €9,089m) benefited from the good operating basis and higher D/A (+12%), but the significantly lower NWC outflow (€-149m after €-817m) and the contribution from discontinued operations (Diabetes Care and CS Consumer)
22 Feb 2017
Suffering CropScience, operating CF’s tide is high
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Suffering CropScience, operating CF’s tide is high
Bayer AG (BAYN:WBO) | 0 0 0.5% | Mkt Cap: 80,975m
- Published:
22 Feb 2017 -
Author:
Martin Schnee -
Pages:
4
Bayer reported +2% (organic: +4%) higher sales at €46,769m and the gross profit margin improved from 54.4% to 56.6% in 2016. EBITDA rose +13% to €10,785m and net profit attributable to shareholders came in at €4,531m, up by +10%. Operating CF (+32% to €9,089m) benefited from the good operating basis and higher D/A (+12%), but the significantly lower NWC outflow (€-149m after €-817m) and the contribution from discontinued operations (Diabetes Care and CS Consumer)